



**Immunomic
Therapeutics**

**Press Release
For Immediate Release**

Immunomic Therapeutics To Present at New York Keiretsu Chapter Life Sciences Forum on November 18, 2009

Rockville, MD, November 10, 2009 — Dr. Bill Hearl, President and CEO of Immunomic Therapeutics, Inc., Rockville, Maryland, announced today that the Company will be featured at the Keiretsu Forum NY Tri-State Life Sciences Forum on November 18, 2009. According to the Keiretsu website, the Life Sciences Forum “is a premier angel group focused on bio-tech and medical device companies. It is composed of experienced angels who are interested in early stage funding of life science companies.”

Commenting on the event, Dr. Hearl said, “We are pleased to have the support of the Keiretsu New York Chapter and to have this great opportunity to present Immunomics to the membership. We believe ITI is ideally situated to be a highly attractive angel investment and I am looking forward to having an opportunity to share our story and business opportunity with this prestigious investment group.”

The event will be held at the law offices of Reed Smith LLC from 8:00 to 12:00. Interested parties should contact Michael Israely at misraely@keiretsuforum.com.

#

About The Keiretsu Forum

With 15 chapters and over 650 accredited investor members throughout the world, Keiretsu Forum (www.keiretsuforum.com) is the largest North American angel investment network. Keiretsu Forum members provide early-stage capital in the range of \$250K-\$2MM to high-quality, diverse investment opportunities and collaborate in the due diligence, but make individual investment decisions.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. (“ITI”) is a privately held clinical stage biotechnology company headquartered in Rockville, Maryland with offices in Baltimore & Lancaster, PA. ITI is developing next generation vaccines based on patented LAMP Technology. Our LAMP-vax™ platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP construct(s) have been validated in human clinical trials (Geron’s GRNVAC1 cancer) and have been applied to a wide breadth of targets including infectious disease (Influenza, HIV, West Nile Virus, Dengue and others), allergy and cancer. More information about ITI and LAMP technology can be obtained from www.immunomix.com.

This press release may contain forward looking statements regarding, among other matters, the Company’s future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI’s technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company’s competitors and other competitive factors.

CONTACT:

Bill Hearl, Ph.D., President & CEO
Immunomic Therapeutics, Inc.
240-731-5232
bhearl@immunomictherapeutics.com